Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
1998-06-12
2001-07-31
Hauda, Karen M. (Department: 1632)
Chemistry: molecular biology and microbiology
Vector, per se
C435S328000, C435S375000, C435S335000, C435S343000, C435S343100, C435S343200, C424S093210, C424S093200
Reexamination Certificate
active
06268214
ABSTRACT:
BACKGROUND OF THE INVENTION
Bone marrow transplant represents hope for survival for many patients who suffer from blood, lymphatic and bone-related disorders, and from depleted marrow cells resulting from intensive chemo- and/or radiotherapy. In an “allogeneic” bone marrow transplantation (“allo-BMT”), bone marrow is transplanted from a donor other than the patient (autologous transplant) or the patient's identical sibling (syngeneic transplant).
Allogeneic BMT is the treatment of choice for many hematologic malignancies, such as leukemia, lymphoma and multiple myolema (1, 2). It is the only curative therapy for chronic myeloid leukemia. Transplantation of allogeneic bone marrow, particularly when employed together with high-dose chemoradiotherapy, has been shown to produce superior results compared to autologous or syngeneic transplants (3).
The advantages associated with allogeneic BMT are limited by the risk of a potentially life-threatening complication, graft versus host disease (GvHD). In performing allogeneic BMT, the patient initially undergoes an immunosuppressive regimen to minimize rejection of the graft. Severe GvHD following allo-BMT can be controlled by: (i) treating the patient to eliminate residual recipient alloreactive T cells, and (ii) treating the graft to remove mature alloreactive T lymphocytes (2).
Removal of alloreactive mature T lymphocytes from the allo-BMT increases the incidence of disease relapse, graft rejection and reactivation of viral infection (4). To counteract these effects, allo-BMT patients have been treated by introducing donor T lymphocytes after a delay following allo-BMT.
Recent studies have shown that delayed introduction of donor T lymphocytes following allo-BMT is a promising therapy for reconstituting immunity and treating relapse of several disease states, and a therapy which could render allo-BMT more efficacious. Patients that underwent treatment with allo-BMT devoid of T lymphocytes, when affected by recurrence of chronic myelogenous leukemia, acute leukemia, lymphoma, and multiple myeloma, could achieve complete remission after the infusion of donor leukocytes, without requiring cytoreductive chemotherapy or radiotherapy (5). In other studies, delayed lymphocyte introduction was used to treat complications related to the severe immunosuppression associated with allo-BMT, such as Epstein-Barr virus-induced B lymphoproliferative disorders (EBV-BLPD) (6, 7) and reactivation of cytomegalovirus (CMV) infection (8).
The therapeutic promise of delayed introduction of donor T lymphocytes following allo-BMT, however, remains limited by GvHD, a frequent and potentially lethal complication of the treatment. Currently, no specific treatment exists for established GvHD. Thus, the threat of GvHD must be weighed heavily against the therapeutic effect of allo-BMT, and limits the applications in which the therapy is employed. (9). Accordingly, a regimen for preventing and for treating GvHD is highly desired in order to permit the beneficial use of delayed introduction of donor T lymphocytes following allo-BMT.
In this delayed lymphocyte introduction therapy, there also is a need for a simple method of monitoring the lymphocytes post-infusion. Effective monitoring would permit an investigator to determine whether the infused lymphocytes contribute to or cause a variety of complications which may occur after infusion. Since complications post-BMT can arise from a variety of origins and since the patients are highly immunosurpressed, rapid determination of the mechanisms underlying complications is highly desired.
Recently, investigators have transduced lymphocytes for delayed introduction with a single selectable marker, the gene, neomycin phosphotransferase (neo). Thereafter, PCR was employed to monitor the gene in cells biopsied from the patient. However, this method is cumbersome and PCR is time consuming (19). For example, prior to infusing the transduced markers into a patient, expression of neo must be verified. Expression of neo in transduced lymphocytes takes about two weeks time. During such time, the lymphocytes grown in culture often undergo self-tranformation and mutation of their original characteristics. Also, during such time, the recipient patient's clinical condition often changes for the worse.
Any vector carrinying a marker gene, to be useful in the present context is safe, efficient, and preferably must not substantially interfere with the lymphocyte's range of immune functions or its longevity (persistence) in the recipient's immune/circulatory system.
Hence, it is desired to provide a vector carrying a marker which permits efficient and fast expression, easy detection, by methods such as fluorescence activated cell sorting, easy monitoring after infusion (particularly of peripheral lymphocytes) and of course, is safe and nonimmunogenic. This would permit better, speedier, specific diagnosis of complications, and concommitantly, more successful treatment.
SUMMARY OF THE INVENTION
An overall objective of the invention is to provide a method useful for bone marrow transplant, that is, where it is desired to replace the hematopoeitic stem cells of a recipient patient with those of another. In particular, it is desired to make allogeneic bone marrow transplantation more efficacious, safer, and available to a larger number of patients. In particular, the present invention provides a method of treating or preventing complications associated with delayed introduction of T lymphocytes to a patient having previously received an allo-BMT depleted of T lymphocytes.
It is another object of the invention to provide a safe, efficient vector for transducing lymphocytes for delayed introduction to a patient having previously received an allo-BMT depleted of T lymphocytes. It is a further objective to provide a vector which does not interfere with the lymphocyte's functions and which will persist in the recipient's system. Such a vector contains at least (i) an easily selectable cell surface marker. Most preferably, the vector also contains (ii) a suicide gene, which can be activated in vivo to trigger cell death should a complication correlated with the transduced cells occur. In a most preferred embodiment, the vector contains only genes (i) and (ii).
It is yet another object of the invention to provide a simple, fast method of monitoring transduced donor lymphocytes according to the invention, after their introduction post allo-BMT. According to the invention, monitoring is performed by obtaining a biological sample suspected of containing transduced lymphocytes from the patient, and detecting the presence or absence of transduced lymphocytes by means of a cell surface marker. In a preferred embodiment, cells are monitored by using florescence activated cell sorting or magnetic sorting (immunobeads).
In another embodiment of the invention, it is possible to monitor and determine whether transduced donor lymphocytes introduced post-BMT are correlated causally to a complication(s) which arises after their introduction. According to this method, a biological sample is taken from the patient and tested to determine the presence of the marker. The results are correlated against the clinical symptoms of the complication. If a positive correlation is made, then the complication can be treated by specific elimination of the transduced cells. This elimination is achieved by use of a “suicide” gene, a negative selectable gene whose expression product renders the transduced cell susceptible (directly or indirectly) to cell death, by administration of a drug, for example.
It is another object of the invention to treat graft versus host disease which may develop with introduction of transduced lymphocytes into an allo-BMT patient. According to this method, the transduced lymphocytes are made sensitive to a particular agent or drug as a result of the expression of the negative selectable suicide gene. Therefore, by administering the appropriate agent/drug to the patient, virtually all of the transduced cells are killed.
I
Bordignon Claudio
Mavilio Fulvio
Arent Fox Kintner & Plotkin & Kahn, PLLC
Beckerleg Anne Marie S
Hauda Karen M.
Roche Diagnostics GmbH
LandOfFree
Vectors encoding a modified low affinity nerve growth factor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vectors encoding a modified low affinity nerve growth factor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vectors encoding a modified low affinity nerve growth factor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2483271